Glycogen Synthase Kinase-3β Inhibition Augments Diabetic Endothelial Progenitor Cell Abundance and Functionality via Cathepsin B: a Novel Therapeutic Opportunity for Arterial Repair
Progenitor cell therapy is hindered in patients with diabetes mellitus (DM) due to cellular senescence. Glycogen synthase kinase 3β (GSK3β) activity is increased in DM potentially exacerbating impaired cell based therapies. Thus, we aimed to determine if and how GSK3β inhibitors (GSKi) can improve therapeutic efficacy of endothelial progenitor cells (EPC) from patients with DM. Patients with DM had fewer EPCs and increased rates of apoptosis. DM-EPCs also exhibited higher levels of GSK3β activity resulting in increased levels of phosphorylated β-catenin. Proteomic profiling of DM EPCs treated with GSKi identified 37 non-redundant, differentially regulated proteins. Cathepsin B (cathB) was subsequently confirmed to be differentially regulated and showed 40% less baseline activity in DM-EPCs – an effect reversed by GSKi treatment. Finally, in vivo efficacy of cell based therapy was assessed in a xenotransplant femoral wire injury mouse model. Administration of DM EPCs reduced the intima:media – an effect that was further augmented when DM EPCs were pre-treated with GSKi, yet absent when cathB was antagonized. In DM, increased basal GSK3β activity contributes to accelerated EPC cellular senescence – an effect reversed by small molecule antagonism of GSK3β which enhances cell based therapy following vascular injury.
- Received June 23, 2013.
- Accepted November 21, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.